Efrain Pacheco Selected Research

Tartrate-Resistant Acid Phosphatase

1/2009

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Efrain Pacheco Research Topics

Disease

2	Arthritis (Polyarthritis) 01/2009 - 10/2002
2	Experimental Arthritis 01/2009 - 10/2002
2	Inflammation (Inflammations) 01/2009 - 10/2002
1	Pathologic Processes 03/2013
1	Wounds and Injuries (Trauma) 03/2009
1	Bone Resorption 01/2009
1	Corneal Neovascularization 10/2002

Drug/Important Bio-Agent (IBA)

2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2009 - 10/2002
1	Monoclonal AntibodiesIBA 03/2013
1	Imatinib Mesylate (Gleevec)FDA Link 03/2009
1	CytokinesIBA 01/2009
1	Dinoprostone (PGE2)FDA Link 01/2009
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2009
1	OsteoprotegerinIBA 01/2009
1	Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)IBA 01/2009
1	LigandsIBA 01/2009
1	Tartrate-Resistant Acid PhosphataseIBA 01/2009
1	Orosomucoid (Seromucoid)IBA 01/2009
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 10/2002
1	Interleukin-1 (Interleukin 1)IBA 10/2002
1	Nylons (Nylon)IBA 10/2002
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 10/2002
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2002
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2002
1	PEGylated soluble tumor necrosis factor receptor IIBA 10/2002

Therapy/Procedure

1	Lasers (Laser) 03/2009
1	Therapeutics 01/2009